GPP
SAGE

Great Point Partners’s Sage Therapeutics SAGE Stock Holding History

Great Point Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-26,000
Closed -$2.49M – 47
2018
Q4 		$2.49M Buy
+26,000
New +$2.98M 0.31% 36

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Great Point Partners's SAGE Position: Q4 2021 in Review

Great Point Partners sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 269,010 shares — an estimated $11.9M sold.

Great Point Partners first reported a position in SAGE in Q2 2016 and held it in 15 quarters. The position peaked at $120M in Q3 2020. 217 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • Great Point Partners reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Great Point Partners sold 269,010 Sage Therapeutics shares in Q4 2021, an estimated $11.9M.
  • Great Point Partners first reported a position in Sage Therapeutics in Q2 2016 and held it in 15 quarters.
  • Great Point Partners's Sage Therapeutics position peaked at $120M in Q3 2020.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.